The increasing digitization of healthcare has driven the rise in wearable devices, notably during the COVID-19 pandemic. Wearable devices continuously track patients’ physiological measurements, such as heart rate, activity, sleep, etc. For patients with cancer, these digital biomarkers may reflect meaningful variation in physical function, symptom burden, quality of life, and risk of adverse events, [1] and have the potential to improve physical activity and quality of life. [2] Despite the growing popularity and recognized benefits of wearable devices, research suggests a low uptake and digital divide in both healthy adults [3] and those with chronic diseases (e.g., cardiovascular disease) [4].